My WebMD Sign In

Please enter email address

Enter your password

Keep me signed in on this computer

Show more Information

If you select "Keep me signed in on this computer", every time you visit WebMD.com you won't have to type your email address and password. This means that a cookie will stay on your computer even when you exit or close your browser which may reduce your levels of privacy and security. You should never select this option if you're using a publicly accessible computer, or if you're sharing a computer with others. Even if you select this option there are some features of our site that still require you to log in for privacy reasons.

Forget your password? Having trouble signing in?

Why should I
sign up for WebMD?

With a WebMD Account you can:

Track your way to weight loss success
Manage your family's vaccinations
Join the conversation

See more benefits Sign Up

Why WebMD?

My WebMD

Show Menu

Facebook Twitter Pinterest

WebMD Home

Brain & Nervous System Health Center

Alzheimer's Disease Health Center

Alzheimer's Disease News

Email a Friend

Print Article

Alzheimer's Disease Health Center

Tools & Resources

Font Size

Experimental Alzheimer's Drug Halted

Drug Flurizan Didn't Meet Maker's Goals in Latest Tests

By Miranda Hitti
WebMD Health News

Reviewed by Louise Chang, MD

July 2, 2008 -- It's the end of the road for Flurizan, an experimental Alzheimer's disease drug, after disappointing results in its latest study.

Myriad Genetics, which was developing Flurizan, says it's discontinuing work on the drug.

In a preliminary study recently published in The Lancet, Flurizan looked like it might slow functional decline in Alzheimer's patients.

But in Flurizan's latest study -- an 18-month trial in patients with mild Alzheimer's disease -- Flurizan didn't meet the researchers' benchmark for its effects on cognition (mental skills) and daily activities.

View Article Sources Sources